Abstract Number: 1283 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. The efficacy and safety of…Abstract Number: 771 • 2012 ACR/ARHP Annual Meeting
Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results
Background/Purpose: Discontinuing anti-TNF therapy after achieving a stable low disease activity (LDA) or remission (REM) state in rheumatoid arthritis (RA) has become an important area…Abstract Number: 349 • 2012 ACR/ARHP Annual Meeting
Preliminary Results From a Controlled Study Assessing the Humoral Immune Response to Vaccines in Rheumatoid Arthritis Patients Treated with Tocilizumab
Background/Purpose: Tocilizumab (TCZ) is an IL-6–receptor inhibitor for treatment of rheumatoid arthritis (RA) patients (pts). Because TCZ may impact how IL-6 modulates T-cell activation and…
- « Previous Page
- 1
- …
- 20
- 21
- 22